Search the Newsreel

Apple, Samsung Can Absorb the Smartphone Cost Shock — Smaller Rivals May Not Be so Lucky

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Apple Inc., Samsung Electronics Co. Ltd. and other major smartphone makers face a tougher demand environment as rising component costs push handset prices higher in the U.S. …

AAOI Stock Pulls Back From 8-Year High As Traders Brace For Q4 Earnings

After IOVA Stock’s Best Day In 2 Years, Analyst Sees Over 300% Upside: Here’s Why

Maplebear (CART) Moved, So What Is Drawing Attention Now?

Maplebear (CART), doing business as Instacart, is gaining attention after its Q2 results showed 14% year-over-year Gross Transaction Value growth, driven by an AI assistant rollout and new partnerships. The company's stock has seen a 23.09% return in 90 days, with a current share …

Rapid7 (RPD) Stock Fair Value Rises After Analysts Lift Targets On Margin Focus

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Rapid7 is back in focus after a reset in price targets, with the fair value estimate moving from US$8.20 to US$11.71 per share. Analysts are clustering new …

Applied Materials Stock Fell 5% After a Record Q3 2026 Quarter. Here’s Where the Stock Could Go

BofA Securities Maintains Aardvark Therapeutics(AARD.US) With Sell Rating

BofA Securities has reiterated its Sell rating on Aardvark Therapeutics (AARD.US). The article does not provide further details regarding the financial implications or the analyst's rationale for maintaining this rating.

Apple gets U.S. warning not to buy Chinese memory chips (AAPL)

The U.S. government has warned Apple against purchasing memory chips from Chinese companies, according to Commerce Secretary Howard Lutnick. This pressure comes amid an AI-driven supply crunch, pushing device makers like Apple to consider Chinese chip suppliers. The U.S. administration is also encouraging Apple …

Apple gets U.S. warning not to buy memory chips from China: WSJ

[Apple Store At Catalonia Square (Plaza Catalunya) in Barcelona in a neoclassic architecture building] Lobro78/iStock Editorial via Getty Images The U.S. government is not in favor of Apple (AAPL [https://seekingalpha.com/symbol/AAPL]) buying memory chips from Chinese companies, Commerce Secretary Howard Lutnick said in an interview, …

Price to earnings forward of Astron Paper & Board Mill Ltd. – NSE:ASTRON

ETFs Investing in TP ICAP Group plc Stocks

Corcept therapeutics chief development officer sells $1.8m in stock

William Guyer, Chief Development Officer at Corcept Therapeutics Inc. (NASDAQ:CORT), sold shares worth approximately $1.85 million on August 10, 2026, through two separate transactions under a 10b5-1 plan. Despite the sales, which occurred while the stock was near its 52-week high, Guyer also acquired …

Is Iovance Biotherapeutics (IOVA) Undervalued As Q2 Earnings Reaffirm Revenue Guidance?

Diluted earnings per share (diluted EPS) of Spero Therapeutics, Inc. – BMV:SPRO

Enterprise value to revenue forward of Astron Paper & Board Mill Ltd. – NSE:ASTRON

Will Rising Revenue but Lower EPS Change Trinity Capital's (TRIN) Investment Narrative After Q2 2026 Results?

Relmada (RLMD) Q2 2026 Earnings Call Transcript

BMO Capital Initiates MapLight Therapeutics(MPLT.US) With Buy Rating, Announces Target Price $20

BMO Capital has initiated coverage on MapLight Therapeutics (MPLT.US) with a Buy rating and set a price target of $20. This indicates a positive outlook from the investment firm regarding the company's future stock performance.

Avalo Therapeutics CMO Mittie Doyle sells $13,580 in stock

Mittie Doyle, CMO at Avalo Therapeutics (NASDAQ:AVTX), sold 679 shares for $13,580 after exercising stock options under a Rule 10b5-1 trading plan. Following these transactions, she directly holds 51,776 shares and 114,413 stock options. This news follows Avalo's inclusion in the Russell 2000 and …

Applied Materials Beat Everything but Wall Street’s Expectations for Margins

NTLA|Intellia Therapeutics Inc|Price:11.910|Chg%:+0.080

PTC Therapeutics Is Maintained at Overweight by Barclays

Barclays has reiterated its 'Overweight' rating on PTC Therapeutics (PTCT). The analyst firm maintained a price target of $70.00 for the company's stock. This indicates a positive outlook from Barclays regarding PTC Therapeutics' future performance.

Applied Materials Beat Every Number and Wall Street Sold the Stock Anyway

Nasdaq, S&P 500 Futures Edge Lower Ahead Of Fed Week, AI Earnings Test: Why POET, ATOM, OGN, QCOM, NTLA Are In Focus

Aperam (ENXTAM:APAM) Stock May Be 40% Undervalued On Cash Flow

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Aperam stock has logged a strong run over the past few years, yet current checks suggest the market price may still sit below …

SNAP Stock Falls Premarket Ahead Of Quarterly Report: Investors Watch User Growth, Ad Sales

Citi, KKR, Apollo among gainers; Berkshire Hathaway, eToro in losers: week's financials wrap

[Old Fashioned Bank Sign] georgeclerk/E+ via Getty Images Wall Street closed out the trading week mixed, with the S&P 500 climbing to another all-time high amid key inflation readings and a steady stream of corporate earnings. State Street Financial Sel Sec SPDR ETF (XLF …

HLS Therapeutics Inc. (TSE:HLS) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Die Applied-Materials-Aktie korrigiert nach Rekordquartal und hoher AI-Erwartung

Outlook Therapeutics (OTLK) CFO Lawrence Kenyon buys 101K shares plus 101K warrants

Outlook Therapeutics' CFO, Lawrence A. Kenyon, purchased 101,010 shares of common stock and 101,010 accompanying warrants in an underwritten public offering on August 14, 2026. The combined offering price was $0.99 per share and warrant, with the warrants immediately exercisable at $1.10 and expiring …

Oxford Square Capital Corp. Plans Monthly Dividend of $0.04 (NASDAQ:OXSQ)

Protagonist Therapeutics (NASDAQ:PTGX) Screens as an Affordable Growth Opportunity

XORTX Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Edgewise Therapeutics CEO Kevin Koch sells $785,042 in stock

Edgewise Therapeutics CEO Kevin Koch sold $785,042 worth of company stock on August 12, 2026, primarily to cover tax obligations related to Restricted Stock Unit vesting. Despite the sales, Mr. Koch also acquired new shares through vesting and was granted additional RSUs and stock …

Next Capital Management LLC Invests $10.52 Million in Blackrock Tcp Capital Corp. $TCPC

Next Capital Management LLC has acquired a new stake of 3.13 million shares in Blackrock Tcp Capital Corp. (TCPC) valued at approximately $10.52 million, making it their 8th largest position. Blackrock Tcp Capital recently reported strong Q2 earnings, beating analyst estimates for both EPS …

Walleye Capital LLC Purchases New Holdings in Apogee Enterprises, Inc. $APOG

Walleye Capital LLC recently acquired a new stake in Apogee Enterprises, purchasing 55,738 shares valued at approximately $2.55 million. Apogee Enterprises exceeded its quarterly earnings estimates and maintains a "Buy" consensus rating from analysts with an average price target of $70.50. The company also …